After allotransplantation, cytomegalovirus (CMV) may be transmitted from the donor organ,
giving rise to primary infection in a CMV negative recipient or reinfection in one who is CMV …

Background: Optimal prophylaxis against cytomegalovirus (CMV) disease for organ
transplant patients at risk for primary infection (donor seropositive, recipient seronegative …

Despite substantial advances made in controlling the effects of cytomegalovirus (CMV)
infection, it remains the single most important pathogen in solid organ transplantation (SOT) …

Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain
one of the most common complications after solid organ transplant (SOT). CMV infection …

Cytomegalovirus (CMV) is the most common viral pathogen in organ transplant recipients.
The patients at highest risk of developing CMV disease are seronegative recipients of …

Currently available, potent antiviral agents have proven highly effective for the prevention of
CMV disease during the time that prophylaxis is employed. However, late‐onset CMV …

Solid-organ and hematopoietic stem cell transplantation have become vital in the treatment
of many illnesses that were previously considered fatal. In 1999, a total of 21,516 solidorgan …

Abstract Ganciclovir-resistant (GanR) cytomegalovirus (CMV) is an emerging clinical
problem in organ transplant recipients, particularly recipients of kidney and pancreas and …

INTRODUCTION: Despite recent advances in prevention and treatment, cytomegalovirus
(CMV) is still a major complication in transplant patients. This study sought to analyze the …

Late-onset cytomegalovirus (CMV) disease commonly occurs after discontinuation of
antiviral prophylaxis. We determined the utility of testing CD8+ T-cell response against CMV …